loading
Schlusskurs vom Vortag:
$17.87
Offen:
$17.96
24-Stunden-Volumen:
1.81M
Relative Volume:
0.71
Marktkapitalisierung:
$2.46B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-8.7783
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-3.10%
1M Leistung:
-6.90%
6M Leistung:
-46.26%
1J Leistung:
-49.06%
1-Tages-Spanne:
Value
$17.66
$18.60
1-Wochen-Bereich:
Value
$17.15
$18.60
52-Wochen-Spanne:
Value
$16.10
$42.47

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Firmenname
Apellis Pharmaceuticals Inc
Name
Telefon
617-977-5700
Name
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Name
Mitarbeiter
710
Name
Twitter
@ApellisPharma
Name
Nächster Verdiensttermin
2024-12-05
Name
Neueste SEC-Einreichungen
Name
APLS's Discussions on Twitter

Vergleichen Sie APLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
17.82 2.46B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-09 Herabstufung BofA Securities Buy → Neutral
2025-05-09 Herabstufung Raymond James Strong Buy → Outperform
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2024-12-17 Herabstufung Goldman Buy → Neutral
2024-11-21 Eingeleitet Morgan Stanley Equal-Weight
2024-10-25 Eingeleitet RBC Capital Mkts Sector Perform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-16 Eingeleitet William Blair Outperform
2024-05-31 Eingeleitet Piper Sandler Neutral
2024-02-05 Hochstufung Jefferies Hold → Buy
2023-12-14 Herabstufung Wells Fargo Overweight → Equal Weight
2023-11-09 Eingeleitet Goldman Buy
2023-11-02 Eingeleitet Mizuho Neutral
2023-10-06 Hochstufung JP Morgan Neutral → Overweight
2023-09-15 Hochstufung Wells Fargo Equal Weight → Overweight
2023-08-29 Bestätigt Citigroup Buy
2023-08-03 Herabstufung JP Morgan Overweight → Neutral
2023-08-01 Herabstufung BofA Securities Buy → Neutral
2023-01-03 Herabstufung Wells Fargo Overweight → Equal Weight
2022-11-10 Herabstufung Jefferies Buy → Hold
2022-07-19 Eingeleitet H.C. Wainwright Buy
2022-06-17 Fortgesetzt Stifel Buy
2022-04-14 Herabstufung ROTH Capital Neutral → Sell
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-11-29 Herabstufung ROTH Capital Buy → Neutral
2021-09-10 Bestätigt BMO Capital Markets Outperform
2021-09-10 Bestätigt Credit Suisse Neutral
2021-09-10 Bestätigt Needham Buy
2021-09-10 Bestätigt Oppenheimer Outperform
2021-09-10 Herabstufung Wedbush Outperform → Neutral
2021-08-19 Eingeleitet Jefferies Buy
2021-08-19 Hochstufung Wedbush Neutral → Outperform
2021-05-21 Eingeleitet UBS Buy
2021-04-16 Eingeleitet Goldman Buy
2020-11-19 Eingeleitet Needham Buy
2020-09-01 Eingeleitet Stifel Buy
2020-07-20 Eingeleitet ROTH Capital Buy
2020-06-17 Eingeleitet BTIG Research Neutral
2020-04-01 Eingeleitet Raymond James Strong Buy
2020-03-31 Eingeleitet BMO Capital Markets Outperform
2020-03-11 Hochstufung Wedbush Underperform → Neutral
2020-01-07 Eingeleitet SVB Leerink Mkt Perform
2019-12-19 Eingeleitet BofA/Merrill Buy
2019-11-22 Eingeleitet Wedbush Underperform
2019-11-05 Eingeleitet Credit Suisse Neutral
2019-08-01 Bestätigt Cantor Fitzgerald Overweight
2019-07-12 Hochstufung JP Morgan Neutral → Overweight
2019-03-29 Eingeleitet Robert W. Baird Outperform
2019-01-23 Herabstufung JP Morgan Overweight → Neutral
2018-07-30 Hochstufung B. Riley FBR Neutral → Buy
2018-05-24 Eingeleitet Cantor Fitzgerald Overweight
2018-04-12 Herabstufung B. Riley FBR, Inc. Buy → Neutral
2018-02-08 Eingeleitet B. Riley FBR, Inc. Buy
Alle ansehen

Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten

pulisher
Jun 18, 2025

Apellis Pharma general counsel Watson sells $93k in stock By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 16, 2025

Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 12, 2025

How To Trade (APLS) - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech

Jun 12, 2025
pulisher
Jun 11, 2025

Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Apellis Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 09, 2025

Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN - Yahoo

Jun 09, 2025
pulisher
Jun 09, 2025

Wealth Enhancement Advisory Services LLC Has $1.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jun 08, 2025
pulisher
Jun 07, 2025

Apellis, Sobi present data from open-label period of Phase 3 VALIANT study - Yahoo Finance

Jun 07, 2025
pulisher
Jun 07, 2025

Apellis Pharmaceuticals (APLS) Reports Promising Phase 3 Study R - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Susta - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals (APLS) Reports Promising Empaveli Data - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? - Yahoo Finance

Jun 06, 2025
pulisher
Jun 06, 2025

Sobi and Apellis data underscore Aspaveli potential - The Pharma Letter

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals, Inc. and Sobi Announce EMPAVELI®? (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals and Sobi Present Promising Phase 3 VALIANT Study Results for EMPAVELI in Treating Rare Kidney Diseases at European Renal Association Congress - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Breakthrough: EMPAVELI Achieves 68% Disease Reduction in Rare Kidney Conditions as FDA Decision Approaches - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

High Growth Tech Stocks To Watch In The US June 2025 - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Ann - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | APLS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Reveals New Insights at Goldman Sachs Healthcare Conference: How to Watch Live - Stock Titan

Jun 04, 2025
pulisher
Jun 03, 2025

Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

Wells Fargo & Company Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 7.7% Following Analyst Upgrade - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

These 10 Stocks Blew Past Expectations - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Apellis Pharmaceuticals (APLS) Receives Price Target Boost from Wells Fargo | APLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Wells Fargo Adjusts Price Target for Apellis (APLS) to $29 | APLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Wells Fargo raises Apellis Pharmaceuticals stock price target to $29 By Investing.com - Investing.com Canada

Jun 02, 2025
pulisher
Jun 02, 2025

Wells Fargo Adjusts Price Target on Apellis (APLS) Amid Product Launch Anticipation | APLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,578 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Apellis Pharmaceuticals Insiders Sell US$3.1m Of Stock, Possibly Signalling Caution - simplywall.st

May 31, 2025
pulisher
May 31, 2025

(APLS) Long Term Investment Analysis - news.stocktradersdaily.com

May 31, 2025
pulisher
May 31, 2025

Equities Analysts Offer Predictions for APLS Q2 Earnings - Defense World

May 31, 2025
pulisher
May 26, 2025

Nuveen Asset Management LLC Has $15.67 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

May 26, 2025
pulisher
May 24, 2025

Citigroup Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World

May 24, 2025
pulisher
May 22, 2025

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts - Benzinga

May 22, 2025
pulisher
May 22, 2025

APLS: Citigroup Lowers Price Target for Apellis Pharmaceuticals | APLS Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Grow - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Growth Outlook | APLS Stock News - GuruFocus

May 22, 2025
pulisher
May 20, 2025

How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com

May 20, 2025
pulisher
May 20, 2025

Apellis Pharmaceuticals Stock: Have Some Patience (NASDAQ:APLS) - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

May 20, 2025
pulisher
May 20, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

May 20, 2025

Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):